Academic Journal
Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness method.
| Τίτλος: | Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness method. |
|---|---|
| Συγγραφείς: | Devi J; Division of Gastroenterology, University of Nebraska Medical Center, Omaha, Nebraska, USA., Samaan S; Division of Gastroenterology, WashU Medicine, St Louis, Missouri, USA., Sehgal P; Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA., Mohamed M; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Vincent M; Division of Gastroenterology, WashU Medicine, St Louis, Missouri, USA., Coombs S; Division of Gastroenterology, WashU Medicine, St Louis, Missouri, USA., Doering M; Division of Gastroenterology, WashU Medicine, St Louis, Missouri, USA., Barnes EL; Division of Gastroenterology and Hepatology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Johnson AM; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA., Yarur AJ; F Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA., Deepak P; Division of Gastroenterology, WashU Medicine, St Louis, Missouri, USA deepak.parakkal@wustl.edu. |
| Πηγή: | BMJ open [BMJ Open] 2026 May 26; Vol. 16 (5), pp. e115709. Date of Electronic Publication: 2026 May 26. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BMJ Publishing Group Ltd, 2011- |
| Ιατρικοί όροι (MeSH): | Inflammatory Bowel Diseases*/complications , Inflammatory Bowel Diseases*/therapy , Inflammatory Bowel Diseases*/epidemiology , Obesity*/complications , Obesity*/therapy , Obesity*/epidemiology , Cardiovascular Diseases* , Consensus Statements as Topic*, Humans ; Comorbidity ; Systematic Reviews as Topic |
| Περίληψη: | Introduction: Obesity and related cardiometabolic comorbidities, including hypertension, dyslipidaemia, diabetes, metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease, are increasingly prevalent among individuals with inflammatory bowel disease (IBD). These conditions influence disease activity, therapeutic response, surgical outcomes and overall quality of life, yet evidence remains fragmented. The Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD) initiative aims to synthesise evidence and generate consensus recommendations to guide practice and future research in this area. This study describes a protocol for a structured evidence synthesis and Research ANd Development/University of California, Los Angeles (RAND/UCLA) Appropriateness Method (RUAM) consensus process. Methods and Analysis: We will conduct three systematic reviews and a structured evidence synthesis organised into three domains: (1) the impact of obesity on IBD outcomes, (2) the burden of cardiometabolic complications in IBD and (3) the management of overweight, obesity and cardiometabolic comorbidities in IBD. A multidisciplinary international panel of gastroenterologists, surgeons, endocrinologists, hepatologists, cardiologists and dietitians will assess each statement using the RAND/UCLA appropriateness method. Panellists will rate the appropriateness of each statement (only those that fall within their area of expertise) on a 1-9 scale (1-3=inappropriate, 4-6=uncertain and 7-9=appropriate), with medians rounded up (eg, 6.5=appropriate). Agreement will be assessed using the RAND Disagreement Index (DI<1.0=agreement). Ethics and Dissemination: This study will not involve direct patient participation, as it is based on evidence synthesis and expert consensus; therefore, formal research ethics committee approval will not be required. Patient representatives will contribute to the consensus process to provide contextual perspectives but no identifiable data will be collected.Findings will be disseminated through publication in peer-reviewed journals, presentation at major gastroenterology and IBD conferences and communication with professional societies. A lay summary and patient-friendly infographic will also be developed to facilitate translation of recommendations into clinical practice. Prospero Registration Numbers: CRD420251178843: a systematic review of the impact of obesity on inflammatory bowel disease outcomes.CRD420251178799: a systematic review of cardiometabolic complications in inflammatory bowel disease.CRD420251174653: management of overweight, obesity and cardiometabolic comorbidities in inflammatory bowel disease: a systematic review. (© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.) |
| Competing Interests: | Competing interests: ELB has received research support from Eli Lilly and Bausch Health/Salix and is the consultant for AbbVie, Boomerang, Eli Lilly, Johnson and Johnson, PharmassêtX, Pfizer, Sanofi, Takeda and Target RWE. AJY has been a consultant for Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Celltrion, Roche, Merck, Boehringer Ingelheim and Johnson and Johnson. AMJ has received research support from AbbVie and Spyre Therapeutics unrelated to the data in this paper and is a consultant for Vilya Therapeutics. PD has received research support under a sponsored research agreement unrelated to the data in the study and/or consulting from Johnson and Johnson, Pfizer, AbbVie, Bristol Myers Squibb, CorEvitas, Takeda Pharmaceuticals, Direct Biologics, Tr1X, Lilly, Teva Pharmaceuticals, Merck, Sanofi, ExeGi Pharmaceuticals, AGMB, Landos Pharmaceuticals, Asahi Kasei and Celltrion. The rest of the authors have no conflicts of interest to declare. The authors declare that this study received no external funding. While several authors are affiliated with the same institutions, these institutions did not provide financial support for this work and had no role in the design, conduct, analysis or reporting of the study. |
| Σχόλια: | Update of: medRxiv. 2025 Dec 22:2025.12.20.25342738. doi: 10.64898/2025.12.20.25342738.. (PMID: 41480017) |
| References: | BMJ Open. 2024 Mar 7;14(3):e074659. (PMID: 38453206) Am J Gastroenterol. 2020 Jun;115(6):832-840. (PMID: 32224703) Am J Gastroenterol. 2025 May 1;120(5):1152-1155. (PMID: 39717004) Aliment Pharmacol Ther. 2022 Apr;55(8):894-907. (PMID: 35274325) Clin Gastroenterol Hepatol. 2023 Mar;21(3):761-770.e13. (PMID: 36075499) Am J Gastroenterol. 2019 Apr;114(4):630-639. (PMID: 30865012) Am J Gastroenterol. 2023 Nov 1;118(11):2005-2013. (PMID: 37207314) J Adv Nurs. 2000 Oct;32(4):1008-15. (PMID: 11095242) Clin Gastroenterol Hepatol. 2025 Oct;23(11S):S1-S60. (PMID: 40874901) Dig Liver Dis. 2005 Jun;37(6):407-17. (PMID: 15893279) Clin Gastroenterol Hepatol. 2019 Dec;17(13):2816-2818. (PMID: 30876963) Dig Dis Sci. 2024 Aug;69(8):2741-2753. (PMID: 38864929) MethodsX. 2020 Dec 13;8:101179. (PMID: 33365260) United European Gastroenterol J. 2020 Dec;8(10):1196-1207. (PMID: 33276710) Endoscopy. 2009 Mar;41(3):218-26. (PMID: 19280533) Int J Technol Assess Health Care. 1986;2(1):53-63. (PMID: 10300718) Gastroenterology. 2023 Oct;165(4):963-975.e5. (PMID: 37499955) Curr Opin Gastroenterol. 2024 Jul 1;40(4):268-275. (PMID: 38662340) J Clin Gastroenterol. 2024 Feb 01;58(2):176-182. (PMID: 36728679) J Crohns Colitis. 2009 Dec;3(4):223-4. (PMID: 21172279) Inflamm Bowel Dis. 2020 Jun 18;26(7):1089-1097. (PMID: 31613968) Med Decis Making. 2004 Mar-Apr;24(2):228-31. (PMID: 15090107) J Crohns Colitis. 2021 Nov 8;15(11):1816-1823. (PMID: 34117877) Clin Gastroenterol Hepatol. 2020 Apr;18(4):881-888.e1. (PMID: 31394285) |
| Contributed Indexing: | Keywords: Bariatric Surgery; Body Mass Index; Inflammation; Inflammatory bowel disease; Obesity |
| Entry Date(s): | Date Created: 20260526 Date Completed: 20260526 Latest Revision: 20260813 |
| Update Code: | 20260813 |
| PubMed Central ID: | PMC13218099 |
| DOI: | 10.1136/bmjopen-2025-115709 |
| PMID: | 42191195 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2044-6055 |
|---|---|
| DOI: | 10.1136/bmjopen-2025-115709 |